Lower occludin abundance was identified as the principal BBB-associated protein alteration in the 3xTg-AD model, with the largest mean reductions observed at 3 (~80%) and 6 months (~68%), alongside exploratory evidence of increased BBB permeability at 3 months.
Key Findings
Results
Occludin was the only junctional protein with a significant overall genotype effect in cerebral capillary-enriched fractions from 3xTg-AD mice compared to Non-Tg mice.
Analysis included claudin-1, -3, -5, occludin, and VE-cadherin in cerebral capillary-enriched fractions
The significant overall genotype effect was detected for occludin across all age groups studied
No significant age or genotype effects were detected for claudin-1, claudin-3, claudin-5, or VE-cadherin
Mice were studied at asymptomatic, early, and advanced stages: 3, 6, 12, and 16 months of age
Protein abundance was assessed by Western blot
Results
The largest reductions in occludin abundance in 3xTg-AD mice were observed at 3 months (~80%) and 6 months (~68%) of age.
The ~80% reduction at 3 months corresponds to the asymptomatic stage of the model
The ~68% reduction at 6 months corresponds to an early disease stage
These reductions were observed in cerebral capillary-enriched fractions from male mice
The analysis was cross-sectional, comparing Non-Tg and 3xTg-AD mice at each time point
Results
A small exploratory cohort showed a higher hemisphere-derived BBB permeability index in 3xTg-AD mice at 3 months using FITC-dextran.
BBB permeability was evaluated using 3-5 kDa FITC-dextran
The permeability experiment was conducted in an independent cohort at 3 months of age
The authors described this as 'exploratory evidence' of increased BBB permeability
The cohort used for permeability was separate from the cohort used for protein abundance assessment
Results
Neither the pSRC/SRC ratio nor the abundance of an MMP-9-immunoreactive band differed significantly between 3xTg-AD and Non-Tg genotypes at 3 months.
pSRC/SRC ratio and MMP-9-immunoreactive band were evaluated as candidate signaling markers related to occludin dysregulation
These markers were assessed in a separate cohort at 3 months of age
No significant genotype differences were found for either marker
pSRC and MMP-9 were selected as candidates because they are known to be involved in occludin regulation
Results
No significant age or genotype effects were detected for pericyte- and endothelial-associated markers across the age groups studied.
Pericyte- and endothelial-associated markers were included as part of the BBB characterization panel
Analysis was performed at 3, 6, 12, and 16 months of age in male Non-Tg and 3xTg-AD mice
The lack of genotype effect for these markers contrasted with the significant occludin finding
Samples were from cerebral capillary-enriched fractions assessed by Western blot
Methods
The study employed an age-stratified, cross-sectional design examining male Non-Tg and 3xTg-AD mice at four time points representing distinct disease stages.
Time points were 3, 6, 12, and 16 months of age, representing asymptomatic, early, and advanced stages
Only male mice were used in this study
Cerebral capillary-enriched fractions were used to assess BBB-associated proteins
Multiple independent cohorts were used: one for protein abundance, one for permeability, and one for signaling markers
The cross-sectional design was noted as a limitation, with longitudinal evaluation recommended for future work
Conclusions
The authors conclude that lower occludin abundance and BBB permeability findings warrant longitudinal and translational evaluation as potential indicators of early neurovascular dysfunction in AD.
The occludin reductions were most prominent at 3 months, the asymptomatic stage, suggesting early onset of BBB-associated protein changes
The authors noted the findings are 'independent observations' requiring further study
The study suggests these markers 'could serve as indicators of early neurovascular dysfunction in AD'
The authors called for both longitudinal studies and translational evaluation to validate these findings
What This Means
This research suggests that in a well-established mouse model of Alzheimer's disease (called the 3xTg-AD model), there is a significant reduction in a key blood-brain barrier protein called occludin — and this reduction appears very early, even before the mice show any outward symptoms of disease. The blood-brain barrier is a protective layer that controls what substances can pass from the bloodstream into the brain. Occludin is one of the proteins that helps form tight junctions, which are essentially the 'seals' that keep this barrier intact. The researchers found that occludin levels were reduced by about 80% at 3 months and 68% at 6 months of age in the Alzheimer's model mice compared to normal mice, while other similar barrier proteins showed no significant differences between the groups.
The study also used a tracer molecule to test whether the blood-brain barrier was actually leaking in the younger Alzheimer's model mice, and found preliminary evidence of increased leakiness at 3 months. However, the researchers tested two potential molecular explanations for the occludin reduction — a signaling molecule called pSRC and an enzyme called MMP-9 — and neither showed significant differences between the groups, leaving the mechanism unexplained. Importantly, the study was cross-sectional (a snapshot in time rather than following the same animals over time) and used only male mice, which are important limitations.
This research suggests that changes in occludin levels at the blood-brain barrier may be an early event in Alzheimer's-related brain changes, potentially occurring before classic disease symptoms appear. If similar patterns were found in humans, occludin or blood-brain barrier integrity could potentially serve as early markers of neurovascular dysfunction in Alzheimer's disease. The authors emphasize that these are preliminary findings that need to be confirmed in longer-term studies and in human research before drawing firm conclusions.